Brian's Empire KE
Brian Kimathi
Supreme Court keeps broader access to abortion pill mifepristone in place while legal fight continues
Supreme Court extended a stay blocking lower-court limits on mifepristone, preserving telehealth prescribing and mail delivery for now
VideoSupreme Court temporarily blocks ruling on abortion pill, restores wider access
Live Action founder and president Lila Rose discusses the Supreme Court temporarily lifting restrictions on access to the abortion drug mifepristone by mail on ‘Fox News @ Night.’
The Supreme Court on Thursday extended its administrative stay blocking enforcement of a lower court ruling that would have restricted access to the abortion pill mifepristone, allowing telehealth prescribing and mail distribution of the drug to continue while the legal battle wages on.
The decision keeps in place current FDA rules allowing patients to obtain mifepristone without an in-person doctor visit.
Justice Clarence Thomas dissented from the court’s order. Justice Samuel Alito also filed a separate dissent.
The case stems from challenges to FDA changes that expanded access to mifepristone in 2023, allowing telehealth prescribing and distribution by mail.
The US Supreme Court during a rain storm in Washington, DC, US, on Friday, Feb. 20, 2026. (Annabelle Gordon/Bloomberg via Getty Images)
A Fifth Circuit ruling previously sought to reinstate previous in-person dispensing requirements. The Supreme Court’s action temporarily blocks the Louisiana court's restrictions while the case continues through the courts.
CLICK HERE TO GET THE FOX NEWS APP
This is a developing story. Check back later for updates.
Jasmine Baehr is a Breaking News Writer for Fox News Digital, where she covers politics, the military, faith and culture.
Support Everyday Chronicle
Global reporting requires independent voices. If you value our coverage, please consider a small contribution to help us grow.
Click the button below to make a secure donation
Discover more from Everyday Chronicle
Subscribe to get the latest posts sent to your email.
Have any thoughts?
Share your reaction or leave a quick response — we’d love to hear what you think!
-
0
-
0
-
0
-
0
-
0
-
0
